A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk
Allan D. Sniderman,Kenneth C. Williams,John H. Contois,Howard M. Monroe,Matthew J. McQueen,Jacqueline de Graaf,Curt D. Furberg +6 more
622
TL;DR: This meta-analysis based on all the published epidemiological studies that contained estimates of the relative risks of non-HDL-C and apoB of fatal or nonfatal ischemic cardiovascular events further validate the value of apo B in clinical care.
read more
Abstract: Background—Whether apolipoprotein B (apoB) or non-high-density lipoprotein cholesterol (HDL-C) adds to the predictive power of low-density lipoprotein cholesterol (LDL-C) for cardiovascular risk remains controversial. Methods and Results—This meta-analysis is based on all the published epidemiological studies that contained estimates of the relative risks of non-HDL-C and apoB of fatal or nonfatal ischemic cardiovascular events. Twelve independent reports, including 233 455 subjects and 22 950 events, were analyzed. All published risk estimates were converted to standardized relative risk ratios (RRRs) and analyzed by quantitative meta-analysis using a random-effects model. Whether analyzed individually or in head-to-head comparisons, apoB was the most potent marker of cardiovascular risk (RRR, 1.43; 95% CI, 1.35 to 1.51), LDL-C was the least (RRR, 1.25; 95% CI, 1.18 to 1.33), and non-HDL-C was intermediate (RRR, 1.34; 95% CI, 1.24 to 1.44). The overall comparisons of the within-study differences showed t...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Scott M. Grundy,Neil J. Stone,Alison L. Bailey,Craig A. Beam,Kim K. Birtcher,Roger S. Blumenthal,Lynne T. Braun,Sarah D. de Ferranti,Joseph Faiella-Tommasino,Daniel E. Forman,Ronald N. Goldberg,Paul A. Heidenreich,Mark A. Hlatky,Daniel W. Jones,Donald M. Lloyd-Jones,Nuria Lopez-Pajares,Chiadi E Ndumele,Carl E. Orringer,Carmen A. Peralta,Joseph J. Saseen,Sidney C. Smith,Laurence S. Sperling,Salim S. Virani,Joseph Yeboah +23 more
TL;DR: The next generation of scientists and decision-makers will be shaped by the experiences of those who have gone before them and will help shape the future of medicine and science.
5.8K
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
David C. Goff,Donald M. Lloyd-Jones,Glen C. Bennett,Sean Coady,Ralph B. D'Agostino,Raymond J. Gibbons,Philip Greenland,Daniel T. Lackland,Daniel Levy,Christopher J. O'Donnell,Jennifer G. Robinson,J. Sanford Schwartz,Susan T. Shero,Sidney C. Smith,Paul D. Sorlie,Neil J. Stone,Peter W.F. Wilson +16 more
TL;DR: Harmon S. Jordan, ScD, Lev Nevo, MD, Janusz Wnek, PhD Jeffrey L. Anderson,MD, FACC, FAHA, Chair-Elect, Nancy M. Halperin, PhD.
5.5K
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
David C. Goff,Donald M. Lloyd-Jones,Faha Glen Bennett,Sean Coady,Jennifer G. Robinson,J. Sanford Schwartz,Raymond J. Gibbons,Susan T. Shero,Philip Greenland,Sidney C. Smith,Daniel T. Lackland,Paul D. Sorlie,Daniel Levy,Neil J. Stone +13 more
TL;DR: The ACC and AHA have collaborated with the National Heart, Lung, and Blood Institute and stakeholder and professional organizations to develop guidelines, standards, and policies that promote optimal patient care and cardiovascular health.
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Donna K. Arnett,Roger S. Blumenthal,Michelle A. Albert,Andrew B. Buroker,Zachary D. Goldberger,Ellen J. Hahn,Cheryl Dennison Himmelfarb,Amit Khera,Donald M. Lloyd-Jones,J. William McEvoy,Erin D. Michos,Michael D. Miedema,Daniel Muñoz,Sidney C. Smith,Salim S. Virani,Kim A. Williams,Joseph Yeboah,Boback Ziaeian +17 more
TL;DR: Patrick T. O’Gara, MD, MACC, FAHA, Chair Joshua A. Beckman,MD, MS, FAha, Chair-Elect Glenn N. Levine, MD., Immediate Past Chair Sana M. Al-Khatib, MD.
4K
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano,Ian D. Graham,Guy De Backer,Olov Wiklund,M. John Chapman,Heinz Drexel,Arno W. Hoes,Catriona Jennings,Ulf Landmesser,Terje R. Pedersen,Željko Reiner,Gabriele Riccardi,Marja-Riitta Taskinen,Lale Tokgozoglu,W. M. Monique Verschuren,Charalambos Vlachopoulos,David R. Wood,José Luis Zamorano +17 more
TL;DR: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and European Atherosclerosis Society and EAS and ABI : ankle-brachial index are formed.
References
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Salim Yusuf,Steven Hawken,Stephanie Ôunpuu,Tony Dans,Alvaro Avezum,Fernando Lanas,Matthew J. McQueen,Andrzej Budaj,Prem Pais,John Varigos,Liu Lisheng +10 more
TL;DR: Abnormal lipids, smoking, hypertension, diabetes, abdominal obesity, psychosocial factors, consumption of fruits, vegetables, and alcohol, and regular physical activity account for most of the risk of myocardial infarction worldwide in both sexes and at all ages in all regions.
12.3K
•Book
Introduction to Meta-Analysis
Michael Borenstein,Larry V. Hedges,Julian P T Higgins,Hannah R. Rothstein +3 more
- 27 Apr 2009
Prediction of Coronary Heart Disease Using Risk Factor Categories
Peter W.F. Wilson,Ralph B. D'Agostino,Daniel Levy,Albert M. Belanger,Halit Silbershatz,William B. Kannel +5 more
TL;DR: A simple coronary disease prediction algorithm was developed using categorical variables, which allows physicians to predict multivariate CHD risk in patients without overt CHD.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Scott M. Grundy,James I. Cleeman,C. Noel Bairey Merz,H. Bryan Brewer,Luther T. Clark,Donald B. Hunninghake,Richard C. Pasternak,Sidney C. Smith,Neil J. Stone +8 more
TL;DR: The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL, and confirm that older persons benefit from therapeutic lowering of LDL-C.
An introduction to meta-analysis.
TL;DR: This paper reviews the use ofMeta-Analysis as a data pooling technique in a non-technical manner and illustrates the type of information that can be obtained from a Meta-Analysis, that is not conventionally available from individual trials.
5.5K
Related Papers (5)
Alberico L. Catapano,Zeljko Reiner,Guy De Backer,Ian D. Graham,Marja-Riitta Taskinen,Olov Wiklund,Stefan Agewall,Eduardo Alegria,M. John Chapman,Paul N. Durrington,Serap Erdine,Julian Halcox,Richard J. Hobbs,John Kjekshus,Pasquale Perrone Filardi,Gabriele Riccardi,Robert F. Storey,David R. Wood +17 more
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more